NOVO.B.DK

305.65

-3.29%↓

HLUNB.DK

38.2

-3.24%↓

AMBUB.DK

82.5

-4.4%↓

NOVO.B.DK

305.65

-3.29%↓

HLUNB.DK

38.2

-3.24%↓

AMBUB.DK

82.5

-4.4%↓

NOVO.B.DK

305.65

-3.29%↓

HLUNB.DK

38.2

-3.24%↓

AMBUB.DK

82.5

-4.4%↓

NOVO.B.DK

305.65

-3.29%↓

HLUNB.DK

38.2

-3.24%↓

AMBUB.DK

82.5

-4.4%↓

NOVO.B.DK

305.65

-3.29%↓

HLUNB.DK

38.2

-3.24%↓

AMBUB.DK

82.5

-4.4%↓

Search

Coloplast A-S (Class B)

Închisă

488.9 -0.45

Rezumat

Modificarea prețului

24h

Curent

Minim

485.4

Maxim

492.1

Indicatori cheie

By Trading Economics

Venit

70M

875M

Vânzări

2M

7B

P/E

Medie Sector

32.582

84.243

EPS

3.88

Randament dividend

4.29

Marjă de profit

12.572

Angajați

16,744

EBITDA

2B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.29%

2.28%

Statistici piață

By TradingEconomics

Capitalizare de piață

-4B

119B

Deschiderea anterioară

489.35

Închiderea anterioară

488.9

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 feb. 2026, 23:26 UTC

Principalele dinamici ale pieței

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb. 2026, 22:31 UTC

Câștiguri

Correction to America Movil 4Q Profit Article

10 feb. 2026, 22:22 UTC

Câștiguri

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb. 2026, 23:51 UTC

Market Talk
Câștiguri

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb. 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb. 2026, 23:40 UTC

Market Talk
Câștiguri

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb. 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb. 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10 feb. 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb. 2026, 22:15 UTC

Câștiguri

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb. 2026, 22:10 UTC

Câștiguri

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb. 2026, 22:10 UTC

Câștiguri

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb. 2026, 22:09 UTC

Câștiguri

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb. 2026, 22:09 UTC

Câștiguri

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb. 2026, 22:01 UTC

Câștiguri

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb. 2026, 21:54 UTC

Câștiguri

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb. 2026, 21:53 UTC

Câștiguri

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb. 2026, 21:51 UTC

Câștiguri

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb. 2026, 21:51 UTC

Câștiguri

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb. 2026, 21:51 UTC

Câștiguri

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb. 2026, 21:51 UTC

Câștiguri

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb. 2026, 21:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb. 2026, 21:50 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb. 2026, 21:50 UTC

Câștiguri

James Hardie Industries 3Q EPS 12c >JHX

10 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 feb. 2026, 21:50 UTC

Câștiguri

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb. 2026, 21:49 UTC

Câștiguri

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb. 2026, 21:49 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb. 2026, 21:48 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb. 2026, 21:47 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Comparație

Modificare preț

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat